MediciNova’s new drugs receive US patent protection

MediciNova, a US biopharmaceutical company has been granted a US patent for its new drugs targeting hypertriglyceridemia, hypercholesterolemia and hyperlipoproteinemia. FDA’ has granted fast track designation and Orphan-drug designation for one of these new drugs. For more information, click here.